Key points are not available for this paper at this time.
There were no statistically significant effects of canakinumab on measures of vascular structure or function. Canakinumab reduced markers of inflammation (high-sensitivity C-reactive protein and interleukin-6), and there were modest increases in levels of total cholesterol and triglycerides. (Safety NCT00995930).
Choudhury et al. (Sat,) studied this question.